Inovio Pharmaceuticals Inc Stock NYSE
Stocks
US45773H1023
Biotechnology & Medical Research
|
End-of-day quote
NYSE
|
||
| - USD | - |
|
| Market Cap | 128M 112M 105M 95.88M 180M 12.28B 180M 1.26B 486M 6.26B 482M 471M 20.19B | P/E 2026 * |
-1.54x | P/E 2027 * | -2.84x |
|---|---|---|---|---|---|
| Enterprise Value | 128M 112M 105M 95.88M 180M 12.28B 180M 1.26B 486M 6.26B 482M 471M 20.19B | EV / Sales 2026 * |
192x | EV / Sales 2027 * | 2.53x |
| Free-Float |
99.67% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Inovio Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 60 | 10/05/2022 |
Peter Kies
DFI | Director of Finance/CFO | 62 | 01/06/2002 |
Michael Sumner
CTO | Chief Tech/Sci/R&D Officer | 60 | 27/06/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Simon Benito
CHM | Chairman | 81 | 03/01/2019 |
David Weiner
BRD | Director/Board Member | 69 | 11/03/2016 |
Wendy Yarno
BRD | Director/Board Member | 71 | 06/12/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.62% | +4.84% | +4.14% | +32.11% | 46.68B | |
| +0.91% | +0.88% | +44.84% | +36.88% | 44.42B | |
| +1.20% | -5.13% | +337.65% | +547.87% | 41.32B | |
| -1.06% | +4.42% | +7.10% | +89.85% | 41.58B | |
| -1.60% | -0.17% | +9.73% | +43.63% | 30.14B | |
| +0.84% | +0.86% | +25.64% | +157.86% | 17.42B | |
| +0.86% | -0.07% | - | - | 15.6B | |
| +1.15% | +7.46% | +25.97% | +43.93% | 15.54B | |
| +0.24% | +14.31% | -8.35% | - | 14.08B | |
| Average | +0.55% | +3.39% | +55.84% | +136.02% | 29.64B | |
| Weighted average by Cap. | +0.60% | +1.94% | +69.50% | +144.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 667K 581K 547K 499K 935K 63.87M 936K 6.56M 2.53M 32.53M 2.5M 2.45M 105M | 50.61M 44.12M 41.56M 37.85M 70.96M 4.85B 71.04M 498M 192M 2.47B 190M 186M 7.97B |
| Net income | -68.03M -59.32M -55.87M -50.88M -95.39M -6.52B -95.51M -669M -258M -3.32B -256M -250M -10.71B | -56.49M -49.25M -46.39M -42.24M -79.2M -5.41B -79.3M -556M -214M -2.76B -212M -207M -8.9B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
